HCW Biologics (NASDAQ: HCWB) has announced positive results from its non-human primate study for second-generation T-cell engagers (TCEs) targeting solid tumors. The company's lead drug candidate demonstrated strong safety profile and tolerance at doses significantly higher than efficacious levels.
The company's proprietary TRBC platform technology has developed TCEs targeting tissue factor and mesothelin, showing potent anti-pancreatic cancer activities in preclinical studies. Key advantages include reduced immunosuppression in tumor microenvironment, cost-effective manufacturing, and potential treatment for multiple solid tumors including pancreatic cancer and glioblastoma.
Notably, preclinical studies showed 100% survival rate in tumor-bearing mice treated with their TCE candidate. The company is now positioned to seek high-value corporate partnerships to advance development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.